You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • THU0430 Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
Psoriatic arthritis
THU0430 Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Gottlieb A, Husni M, Shuler C, et al
THU0430 Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Annals of the Rheumatic Diseases 2016;75:345.